Availability of Enhanced Computational Tools for Pharmacogenomics and Genome Sequencing to Influence Computational Biology Market Growth
Advancements in technology have resulted in the development of improved tools that are used across various industrial applications and biotechnology is no exception. The availability of enhanced computational tools and their use in genome sequencing is poised to trigger demand for computational biology and associated services across a multitude of applications such as pharmacogenomics, drug discovery, biological simulation, disease modelling, preclinical drug development and in body simulation software. Computed programs are used in designing primers polymerase chain reaction (PCR). They also translate various DNA sequences to amino acid sequences. The availability of such sequence analysis and databases provides detailed information such as gene structure and their encoded message to scientists. This facilitates efficiency improvement of the entire drug design development by carrying out identification protein sequences that are functionally vital. This has fuelled the use of computational tools for sifting out crucial proteins from genomic databases, which is expected to boost the growth of the computational biology market.
Application of Computational Biology in Cellular and Biological Simulations to Give an Impetus to the Market Valuation
Application of computational biology in cellular and biological simulation is expected to increase at a significant rate on the global front. Biological simulation and computational cell modelling support in deciphering physiological and biological functions of cells. In addition, burgeoning cases of unmet medical demands coupled with increasing need for personalised medicine are likely to fuel of computational biology in cellular and biological simulations. In this backdrop, companies are offering tools for personalised medicine to improve patient success. For instance, Hewlett Packard’s high performance computing ability is deployed in personalised medicine in a bid to enhance patient diagnosis facilitating healthcare delivery. That said, growing use in cellular and biological simulation is expected to largely contribute towards value growth of the computational biology market.
North America Likely to Maintain Dominance in the Computational Biology Market; Europe to Follow Suit
Geographically, developed nations across North America are expected to continue with their stronghold with regards to adoption of computational biology. This is mainly owing to rapid growth and acceptance of technology in the field of biology and pharmaceuticals coupled with increasing presence of major players in the computational biology market in the region. Moreover, rampant growth of IT sector backed by factorable business environment across countries such as US, and Canada has resulted in an increase in the number of start-ups involved in drug development and drug discovery and its efficacy using modern techniques. In addition, synthetic biology has gained high traction in United States. This is an emerging discipline that involves reprogramming, creation, and control of various biological systems. Furthermore, rising investment by government bodies in development of computational biology remains a crucial factor driving the market’s growth in North America.
Alternatively, adoption of computational biology in Europe is expected to increase significantly in the coming years. This can be attributed towards high investment in order to improve research by the government along with increasing collaborations between academic institutions and government bodies. For instance, government of Switzerland has set plans to raise investments in the systems biology space as an effort to become a leader in systems biology. Moreover, in 2021, a MoU (Memorandum of Understanding) was signed between Swiss Confederation and World Health Organization (WHO) to develop WHO Biohub Facility, the first in its kind, as a part of WHO Biohub System. Established in Switzerland (in Spiez), this facility serves as a vital centre storage, preparation and sequencing of biological material and its distribution to laboratories. On the other hand, Horizon 2020 program also received huge investment from the European Commission as an effort to remove barriers impacting innovation alongside facilitating improved collaboration between private and public sectors to boost innovation. Such attempts are expected to aid the growth of the computational biology market in developed countries of Europe in the following years.
Computational Biology Market: Competitive Scenario
Biotechnology companies are leveraging computational biology to identify new peptide therapeutics against various indications. For instance, in 2021, Peptilogics used computational biology to discover new peptide therapeutics and announced completion of phase 1 of the clinical trial for its PLG0206 that can be used in the treatment of PJI (Prosthetic Joint Infections). Similarly, same year in January, AsclepiX Therapeutics Inc. leveraged computational biology to discover effective peptide regulators of cellular and vascular homeostasis for treating oncologic and retinal diseases. It announced that first dose has been administered in the patient as a part of its phase ½a clinical trials to access the bioactivity and safety of AXT107 in individuals suffering from DME (Diabetic Macular Edema).
Few of the major players in the computational biology market include Dassault Systemes SE, Compugen Ltd., Genedata AG, Chemical Computing Group ULC, Instem PLC, Rhenovia Pharma SAS, and Accelrys.
The global computational biology market is segmented as below:
By Application
By Services
By End Use
By Region
Key Elements Included In The Study: Global Computational Biology Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Disclaimer:
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.
View Methodology